evolocumab
Selected indexed studies
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. (Circulation, 2022) [PMID:36031810]
- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (N Engl J Med, 2026) [PMID:41211925]
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. (Clin Pharmacokinet, 2018) [PMID:29353350]
_Worker-drafted node — pending editorial review._
Connections
evolocumab is a side effect of
Sources
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. (2022) pubmed
- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. (2026) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. (2018) pubmed
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. (2022) pubmed
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. (2016) pubmed
- Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. (2024) pubmed
- A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. (2014) pubmed
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). (2018) pubmed
- Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. (2015) pubmed
- Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). (2019) pubmed